Cover Story: Wellness in MS

“What are we having for dinner?” is probably one of the most common questions that is asked each and every evening across America. So many choices are available! Whether dining at fast-food restaurants or gourmet eateries, ordering take-out, having a pizza delivered, or cooking at home – deciding on an option can be overwhelming… much less deciding on a healthy one!

Read News Article

Up Front: Now and Then

This title seems particularly timely as I am writing what is probably my last column as President & CEO of MSAA. I am retiring at the end of this year, and with MSAA’s move to our new headquarters at 375 Kings Highway North in Cherry Hill, New Jersey, I was transferring old files when I came across the Spring 1999 edition of The Motivator…where I wrote my first column.

Read News Article

Ask the Doctor: PML Risk and JC Virus

Q: I was diagnosed with relapsing-remitting multiple sclerosis in 1987. I am a 67-yearold female who is mobile, independent, and able to take care of myself without assistance. Initially, I was placed on methotrexate for about four years. I was then placed on Avonex and tolerated the weekly intramuscular injections for about 13 years. The only side effect I experienced was the flu-like symptoms.

Read News Article

Thoughts about Giving: Sustaining Gifts

Thanks to our generous donors, Mary received a cooling vest through MSAA. Now she is able to enjoy going to her grandson’s baseball games and spend time in her garden. Tamara received a rolling walker that allows her to walk farther and with less fatigue, meaning she has been able to enjoy family trips for the first time in years.

Read News Article

Ocrelizumab Shows Positive Results in Treating PPMS

Genentech announced today that ocrelizumab, an investigational medicine for the long-term treatment of relapsing forms of MS, has also shown positive study results in their Phase III ORATORIO study with primary-progressive multiple sclerosis (PPMS). This is the first medication to show positive effects on disability with this form of the disease, which affects approximately 10 percent of the MS population.

Read News Article

Electronic Autoinjector Approved for Betaseron®

On September 25, 2015, the United States Food and Drug Administration (FDA) approved Betaconnect, an electronic autoinjector for use with Betaseron® (interferon beta-1b), an approved disease-modifying therapy (DMT) for the treatment of relapsing-remitting multiple sclerosis (RRMS). Although other autoinjectors are available to help with the administration of self-injected medications, this is the first electronic autoinjector to be approved by the FDA for a medication used in the long-term treatment of multiple sclerosis (MS).

Read News Article